Published in Oncol Lett on May 11, 2012
Liver resection and ablation for metastatic melanoma: A single center experience. J Surg Oncol (2015) 0.80
Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma. J Clin Oncol (2009) 6.44
Neoadjuvant treatment of regional stage IIIB melanoma with high-dose interferon alfa-2b induces objective tumor regression in association with modulation of tumor infiltrating host cellular immune responses. J Clin Oncol (2006) 1.83
Surgery for abdominal metastases of cutaneous melanoma. World J Surg (2001) 1.33
Phase II multicenter study of neoadjuvant biochemotherapy for patients with stage III malignant melanoma. J Clin Oncol (2006) 1.03
Management of metastatic melanoma 2005. Surg Oncol Clin N Am (2006) 0.97
A phase II study of neoadjuvant biochemotherapy for stage III melanoma. Cancer (2002) 0.94
Phase II study of neoadjuvant concurrent biochemotherapy in melanoma patients with local-regional metastases. Melanoma Res (1998) 0.92
Phase II study of temozolomide plus pegylated interferon-alpha-2b for metastatic melanoma. Cancer (2006) 0.91
Can surgeons improve survival in stage IV melanoma? J Surg Oncol (2008) 0.89
Multidisciplinary management of special melanoma situations: oligometastatic disease and bulky nodal sites. Curr Oncol Rep (2007) 0.86
Concurrent chemobiotherapy with cisplatin, dacarbazine, decrescendo interleukin-2 and interferon alpha2b in patients with metastatic melanoma. Oncol Rep (2008) 0.84
Prolonged survival in patients with advanced melanoma treated with neoadjuvant chemotherapy followed by resection. Ann Plast Surg (1996) 0.84
A sequential four-drug chemotherapy and biotherapy with interferon alpha and GM-CSF--an innovative protocol for the treatment of metastatic melanoma. Cancer Biother Radiopharm (1998) 0.83
Induction chemotherapy: to downgrade aggressive cancers to improve curability by surgery and/or radiotherapy. Eur J Surg Oncol (2001) 0.80
Sustained complete remission after chemobiohormonal therapy for metastatic melanoma. Am J Clin Oncol (1999) 0.79
Pembrolizumab versus Ipilimumab in Advanced Melanoma. N Engl J Med (2015) 8.64
Improved overall survival in melanoma with combined dabrafenib and trametinib. N Engl J Med (2014) 5.65
Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma. J Clin Oncol (2013) 5.36
Clinical responses in a phase II study using adoptive transfer of short-term cultured tumor infiltration lymphocytes in metastatic melanoma patients. Clin Cancer Res (2010) 3.02
TIL therapy broadens the tumor-reactive CD8(+) T cell compartment in melanoma patients. Oncoimmunology (2012) 1.78
Adoptive transfer of tumor-infiltrating lymphocytes in patients with metastatic melanoma: intent-to-treat analysis and efficacy after failure to prior immunotherapies. Clin Cancer Res (2013) 1.47
Patterns of recurrence in patients with melanoma after radical lymph node dissection. Arch Surg (2005) 1.44
MDR1 expression identifies human melanoma stem cells. Biochem Biophys Res Commun (2008) 1.41
Is the delay in starting postoperative radiotherapy a key factor in the outcome of advanced (T3 and T4) laryngeal cancer? Otolaryngol Head Neck Surg (2004) 1.40
Minimally cultured or selected autologous tumor-infiltrating lymphocytes after a lympho-depleting chemotherapy regimen in metastatic melanoma patients. J Immunother (2009) 1.25
Establishment and large-scale expansion of minimally cultured "young" tumor infiltrating lymphocytes for adoptive transfer therapy. J Immunother (2011) 1.20
MicroRNA-mediated loss of ADAR1 in metastatic melanoma promotes tumor growth. J Clin Invest (2013) 1.11
Primary squamous cell carcinoma (SqCC) of the breast. Am J Clin Oncol (2003) 1.11
Lymphatic drainage to the popliteal basin in distal lower extremity malignant melanoma. Arch Surg (2004) 1.07
Regulation of cancer aggressive features in melanoma cells by microRNAs. PLoS One (2011) 1.07
Systemic dysregulation of CEACAM1 in melanoma patients. Cancer Immunol Immunother (2010) 1.02
Dynamic expression of protective CEACAM1 on melanoma cells during specific immune attack. Immunology (2008) 0.99
A comparative analysis of total serum miRNA profiles identifies novel signature that is highly indicative of metastatic melanoma: a pilot study. Biomarkers (2013) 0.96
Inhibition of human tumor-infiltrating lymphocyte effector functions by the homophilic carcinoembryonic cell adhesion molecule 1 interactions. J Immunol (2006) 0.95
Final results of phase III SYMMETRY study: randomized, double-blind trial of elesclomol plus paclitaxel versus paclitaxel alone as treatment for chemotherapy-naive patients with advanced melanoma. J Clin Oncol (2013) 0.92
Novel immunotherapy for malignant melanoma with a monoclonal antibody that blocks CEACAM1 homophilic interactions. Mol Cancer Ther (2012) 0.89
Predicting and controlling the reactivity of immune cell populations against cancer. Mol Syst Biol (2009) 0.88
Nicotinamide inhibits vasculogenic mimicry, an alternative vascularization pathway observed in highly aggressive melanoma. PLoS One (2013) 0.87
Ras oncoproteins transfer from melanoma cells to T cells and modulate their effector functions. J Immunol (2012) 0.86
Natural killer lysis receptor (NKLR)/NKLR-ligand matching as a novel approach for enhancing anti-tumor activity of allogeneic NK cells. PLoS One (2009) 0.85
Concurrent chemobiotherapy with cisplatin, dacarbazine, decrescendo interleukin-2 and interferon alpha2b in patients with metastatic melanoma. Oncol Rep (2008) 0.84
Are solitary breast papillomas entirely benign? Arch Surg (2003) 0.83
Novel anti-melanoma immunotherapies: disarming tumor escape mechanisms. Clin Dev Immunol (2012) 0.82
Risk factors for lymph node metastases in breast ductal carcinoma in situ with minimal invasive component. Arch Surg (2002) 0.81
Focus on adoptive T cell transfer trials in melanoma. Clin Dev Immunol (2010) 0.81
Adoptive immunotherapy of advanced melanoma. Curr Treat Options Oncol (2012) 0.81
Differences in cytokine levels in melanoma patients with and without redness (Brenner sign). Anticancer Res (2009) 0.80
Preclinical evaluation of adoptive cell therapy for patients with metastatic renal cell carcinoma. Anticancer Res (2009) 0.80
Adoptive cell therapy with autologous tumor-infiltrating lymphocytes and high-dose interleukin-2 for metastatic melanoma: The surgeon's perspective. Exp Ther Med (2012) 0.79
Development of allogeneic NK cell adoptive transfer therapy in metastatic melanoma patients: in vitro preclinical optimization studies. PLoS One (2013) 0.79
Adoptive cell therapy for metastatic melanoma patients: pre-clinical development at the Sheba Medical Center. Isr Med Assoc J (2006) 0.79
Immunotherapy for the management of advanced melanoma: the next steps. Am J Clin Dermatol (2013) 0.79
Mutagen-specific mutation signature determines global microRNA binding. PLoS One (2011) 0.79
Adoptive T-cell transfer in melanoma. Immunotherapy (2013) 0.79
Collection of large-scale expanded lymphocyte cultures for adoptive immunotherapy using a COBE Spectra apheresis machine. J Immunother (2008) 0.78
"Gloves-and-socks" melanoma: does histology make a difference? Dermatol Surg (2008) 0.78
Tumor-Infiltrating Lymphocytes: Clinical Experience. Cancer J (2015) 0.78
Pigmented lesions clinic for early detection of melanoma: preliminary results. Isr Med Assoc J (2007) 0.78
Melanoma early detection and awareness: how countries developing melanoma awareness programs could benefit from melanoma-proficient countries. Am J Ther (2015) 0.77
CXCR1 as a novel target for directing reactive T cells toward melanoma: implications for adoptive cell transfer immunotherapy. Cancer Immunol Immunother (2012) 0.77
Older age and second skin cancer as prognostic factors in localized malignant melanomas. Oncol Rep (2003) 0.77
Who benefits most from adjuvant interferon treatment for melanoma? Am J Ther (2015) 0.76
Germline analysis of thymidine/guanidine polymorphism at position 309 of the Mdm2 promoter in malignant melanoma patients. Melanoma Res (2009) 0.76
Metastatic Lung Lesions as a Preferred Resection Site for Immunotherapy With Tumor Infiltrating Lymphocytes. J Immunother (2016) 0.76
Carcinoembryonic antigen cell adhesion molecule-1 (CEACAM1) in posterior uveal melanoma: correlation with clinical and histological survival markers. Invest Ophthalmol Vis Sci (2011) 0.75
Liver laceration following blunt wave trauma. Isr Med Assoc J (2003) 0.75
Weird activity and the wandering spleen. Isr Med Assoc J (2005) 0.75
Impaired platelet aggregation in melanoma patients treated with interferon-alpha-2b adjuvant therapy. Cancer (2002) 0.75
Adoptive Cell Therapy for Metastatic Melanoma. Cancer J (2017) 0.75
Sentinel node guided surgery for melanoma in the head and neck region. Melanoma Res (2004) 0.75
[Tuberculosis in a pair of twins--the use of molecular biology methods for the detection of the source of infection]. Harefuah (2007) 0.75
CT halo sign as an imaging marker for response to adoptive cell therapy in metastatic melanoma with pulmonary metastases. Eur Radiol (2014) 0.75
Outcome of thick (> 4 mm) node-negative melanomas. Isr Med Assoc J (2009) 0.75